Insights from 2023 ASH Annual Meeting
Video Player is loading.
10 seconds
Playback speed
ASH 2023 Insights: "Oral Decitabine/Cedazuridine (ASTX727) & Venetoclax in Combination With IDH1 or IDH2 Inhibitor Therapy for IDHmut AML"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Himachandana Atluri
By
Insights from 2023 ASH Annual Meeting
FEATURING
Himachandana Atluri
Comments 0
Login to view comments.
Click here to Login
